Haustein J, Schuhmann-Giampieri G
Department of Clinical Research Diagnostics, Schering AG Berlin, F.R.G.
Eur J Radiol. 1990 Nov-Dec;11(3):227-9. doi: 10.1016/0720-048x(90)90064-i.
After intravenous administration of Gd-DTPA (0.1 mmol/kg) hemodialysis was performed five times within 6 days in a patient with endstage renal failure. During the fifth hemodialysis a blood sample of 5 ml was withdrawn and Gd-concentration was measured in plasma at 342.247 nm using the method of Inductively Coupled Plasma Atomic Emission Spectrometry. Gd-concentration measured in venous and arterial blood was 6 x 10(-6) mol/liter, corresponding to 1.5% of the dose administered. If these data can be confirmed in more patients with endstage renal failure, this is the proof of effective hemodialysis of Gd-DTPA in a clinical setting.
在一名终末期肾衰竭患者静脉注射钆喷酸葡胺（0.1 mmol/kg）后，于6天内进行了5次血液透析。在第5次血液透析期间，采集了5 ml血样，并采用电感耦合等离子体原子发射光谱法在342.247 nm波长下测定血浆中的钆浓度。静脉血和动脉血中测得的钆浓度均为6×10⁻⁶摩尔/升，相当于给药剂量的1.5%。如果这些数据能在更多终末期肾衰竭患者中得到证实，这将证明在临床环境中钆喷酸葡胺可通过血液透析有效清除。
